Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Doravirine and Rifapentine/Isoniazid Drug Interaction Study
NCT03886701Phase 1Completed
- Start
- Apr 2019
- Primary completion
- May 2019
- Countries
- 1
01
Overview
Phase 1, open-label, single-arm trial of doravirine in human immunodeficiency virus infection (HIV). Primary endpoints: Doravirine Maximum Concentration at Day 21, Doravirine Area Under the Plasma Concentration Versus Time Curve From 0 to 12 Hours and 1 more. Started Apr 2019; status: completed.
02
Drugs
doravirine
03
Conditions
human immunodeficiency virus infection (HIV)
Beyond the preview
Go deeper on NCT03886701.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03886701.